Integra LifeSciences Holdings Corporation (IART): Price and Financial Metrics

Integra LifeSciences Holdings Corporation (IART): $29.00

0.10 (+0.35%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

IART Price/Volume Stats

Current price $29.00 52-week high $46.75
Prev. close $28.90 52-week low $22.36
Day low $28.57 Volume 1,751,600
Day high $29.38 Avg. volume 920,885
50-day MA $29.21 Dividend yield N/A
200-day MA $36.85 Market Cap 2.29B

IART Stock Price Chart Interactive Chart >


Integra LifeSciences Holdings Corporation (IART) Company Bio


Integra LifeSciences develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neuro-surgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. The company was founded in 1989 and is based in Plainsboro, New Jersey.


IART Latest News Stream


Event/Time News Detail
Loading, please wait...

IART Latest Social Stream


Loading social stream, please wait...

View Full IART Social Stream

Latest IART News From Around the Web

Below are the latest news stories about INTEGRA LIFESCIENCES HOLDINGS CORP that investors may wish to consider to help them evaluate IART as an investment opportunity.

Integra (IART) to Advance ENT Division With New Buyout Deal

Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.

Yahoo | December 14, 2023

Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent®

The acquisition will become part of Integra’s Codman Specialty Surgical (CSS) division. The ear, nose and throat (ENT) category is a key area of strategic interest and highly complementary to the neurosurgery segment.Provides a unique opportunity to build scale and capture a leadership position in the attractive ENT device segment with Acclarent’s established commercial scale, strong brand recognition, differentiated portfolio, and robust innovation pipeline. Generates shareholder value; transac

Yahoo | December 13, 2023

Integra to buy J&J’s Acclarent for $275M

Integra said the purchase, which includes a portfolio of balloon dilation products for the sinuses and eustachian tube, would make it a market leader in ENT procedures.

Yahoo | December 13, 2023

Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors

Jeff Graves Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors PRINCETON, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company’s board of directors, effective immediately. With the appointment of Dr. Graves, Integra has added four new directors since 202

Yahoo | December 12, 2023

Integra Gains From New Product Launches, Mounting Costs Ail

Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.

Yahoo | December 5, 2023

Read More 'IART' Stories Here

IART Price Returns

1-mo 7.49%
3-mo -15.77%
6-mo -34.96%
1-year -28.68%
3-year -57.80%
5-year -45.58%
YTD -33.41%
2023 -22.33%
2022 -16.30%
2021 3.19%
2020 11.39%
2019 29.22%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!